Recent advances in RNAi-based strategies for Therapy and Prevention of HIV-1/AIDS.

Author Information (click to view)

Swamy MN, Wu H, Shankar P,

Swamy MN, Wu H, Shankar P, (click to view)

Swamy MN, Wu H, Shankar P,

Share on FacebookTweet about this on TwitterShare on LinkedIn

Advanced drug delivery reviews 2016 3 21() pii 10.1016/j.addr.2016.03.005


RNA interference (RNAi) provides a powerful tool to silence specific gene expression and has been widely used to suppress host factors such as CCR5 and/or viral genes involved in HIV-1 replication. Newer nuclease-based gene-editing technologies, such as zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN) and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, also provide powerful tools to ablate specific genes. Because of differences in co-receptor usage and the high mutability of the HIV-1 genome, a combination of host factors and viral genes needs to be suppressed for effective prevention and treatment of HIV-1 infection. Whereas the continued presence of small interfering/short hairpin RNA (si/shRNA) mediators is needed for RNAi to be effective, the continued expression of nucleases in the gene-editing systems is undesirable. Thus, RNAi provides the only practical way for expression of multiple silencers in infected and uninfected cells, which is needed for effective prevention/treatment of infection. There have been several advances in the RNAi field in terms of si/shRNA design, targeted delivery to HIV-1 susceptible cells, and testing for efficacy in preclinical humanized mouse models. Here, we comprehensively review the latest advances in RNAi technology towards prevention and treatment of HIV-1.

Submit a Comment

Your email address will not be published. Required fields are marked *

6 − 1 =